245 related articles for article (PubMed ID: 25663437)
1. Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells.
Deissler HL; Lang GK; Lang GE
Graefes Arch Clin Exp Ophthalmol; 2015 Jun; 253(6):885-94. PubMed ID: 25663437
[TBL] [Abstract][Full Text] [Related]
2. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
[TBL] [Abstract][Full Text] [Related]
3. VEGF but not PlGF disturbs the barrier of retinal endothelial cells.
Deissler HL; Deissler H; Lang GK; Lang GE
Exp Eye Res; 2013 Oct; 115():162-71. PubMed ID: 23891860
[TBL] [Abstract][Full Text] [Related]
4. Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells.
Deissler HL; Rehak M; Busch C; Wolf A
Exp Eye Res; 2022 Mar; 216():108945. PubMed ID: 35038456
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells.
Deissler HL; Deissler H; Lang GE
Br J Ophthalmol; 2011 Aug; 95(8):1151-6. PubMed ID: 21273213
[TBL] [Abstract][Full Text] [Related]
6. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.
Deissler HL; Deissler H; Lang GE
Br J Ophthalmol; 2012 Jul; 96(7):1023-8. PubMed ID: 22539748
[TBL] [Abstract][Full Text] [Related]
7. Ranibizumab efficiently blocks migration but not proliferation induced by growth factor combinations including VEGF in retinal endothelial cells.
Deissler HL; Deissler H; Lang GK; Lang GE
Graefes Arch Clin Exp Ophthalmol; 2013 Oct; 251(10):2345-53. PubMed ID: 23760670
[TBL] [Abstract][Full Text] [Related]
8. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells.
Deissler H; Deissler H; Lang S; Lang GE
Br J Ophthalmol; 2008 Jun; 92(6):839-43. PubMed ID: 18511543
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of protein kinase C is not sufficient to prevent or reverse effects of VEGF165 on claudin-1 and permeability in microvascular retinal endothelial cells.
Deissler HL; Deissler H; Lang GE
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):535-42. PubMed ID: 19643968
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Single Routes of Intracellular Signaling is Not Sufficient to Neutralize the Biphasic Disturbance of a Retinal Endothelial Cell Barrier Induced by VEGF-A165.
Deissler HL; Lang GK; Lang GE
Cell Physiol Biochem; 2017; 42(4):1493-1513. PubMed ID: 28719888
[TBL] [Abstract][Full Text] [Related]
11. VEGF receptor 2 inhibitor nintedanib completely reverts VEGF-A
Deissler HL; Stutzer JN; Lang GK; Grisanti S; Lang GE; Ranjbar M
Exp Eye Res; 2020 May; 194():108004. PubMed ID: 32184103
[TBL] [Abstract][Full Text] [Related]
12. Transport and fate of aflibercept in VEGF-A
Deissler HL; Sommer K; Lang GK; Lang GE
Exp Eye Res; 2020 Sep; 198():108156. PubMed ID: 32712182
[TBL] [Abstract][Full Text] [Related]
13. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A.
Yang J; Wang X; Fuh G; Yu L; Wakshull E; Khosraviani M; Day ES; Demeule B; Liu J; Shire SJ; Ferrara N; Yadav S
Mol Pharm; 2014 Oct; 11(10):3421-30. PubMed ID: 25162961
[TBL] [Abstract][Full Text] [Related]
14. Internalization of bevacizumab by retinal endothelial cells and its intracellular fate: Evidence for an involvement of the neonatal Fc receptor.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2016 Feb; 143():49-59. PubMed ID: 26481553
[TBL] [Abstract][Full Text] [Related]
15. Modulation of VEGF-induced retinal vascular permeability by peroxisome proliferator-activated receptor-β/δ.
Suarez S; McCollum GW; Bretz CA; Yang R; Capozzi ME; Penn JS
Invest Ophthalmol Vis Sci; 2014 Nov; 55(12):8232-40. PubMed ID: 25406289
[TBL] [Abstract][Full Text] [Related]
16. Comparison of choroidal and retinal endothelial cells: characteristics and response to VEGF isoforms and anti-VEGF treatments.
Stewart EA; Samaranayake GJ; Browning AC; Hopkinson A; Amoaku WM
Exp Eye Res; 2011 Nov; 93(5):761-6. PubMed ID: 21970900
[TBL] [Abstract][Full Text] [Related]
17. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
Klettner A; Grotelüschen S; Treumer F; Roider J; Hillenkamp J
Br J Ophthalmol; 2015 Jun; 99(6):864-9. PubMed ID: 25740806
[TBL] [Abstract][Full Text] [Related]
18. [The revolution in the treatment of retinal diseases: anti-VEGF treatment at the Assuta Eye Institute].
Katz G; Zehavi C; Treister G
Harefuah; 2015 Apr; 154(4):270-3, 278. PubMed ID: 26065226
[TBL] [Abstract][Full Text] [Related]
19. Pigment epithelium-derived factor inhibits vascular endothelial growth factor-and interleukin-1beta-induced vascular permeability and angiogenesis in retinal endothelial cells.
Sheikpranbabu S; Ravinarayanan H; Elayappan B; Jongsun P; Gurunathan S
Vascul Pharmacol; 2010; 52(1-2):84-94. PubMed ID: 20006737
[TBL] [Abstract][Full Text] [Related]
20. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
Giurdanella G; Anfuso CD; Olivieri M; Lupo G; Caporarello N; Eandi CM; Drago F; Bucolo C; Salomone S
Biochem Pharmacol; 2015 Aug; 96(3):278-87. PubMed ID: 26056075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
